{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:25:13Z","timestamp":1784899513433,"version":"3.55.0"},"reference-count":79,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2 despite its close relation to the SARS-CoV virus that caused a similar epidemic in 2003. Thus, there remains an urgent need for the identification and development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (Mpro) of SARS-CoV-2. A screening of such a vast chemical space for SARS-CoV-2 Mpro inhibitors has not been reported before. After shape screening, two docking protocols were applied followed by the determination of molecular descriptors relevant for pharmacokinetics to narrow down the number of initial hits. Next, molecular dynamics simulations were conducted to validate the stability of docked binding modes and comprehensively quantify ligand binding energies. After evaluation of potential off-target binding, we report a list of 12 purchasable compounds, with binding affinity to the target protease that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order to quickly advise ongoing therapeutic intervention for patients, we evaluated approved antiviral drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore, we identified the natural compounds (\u2212)-taxifolin and rhamnetin as potential inhibitors of Mpro. Rhamnetin is already commercially available in pharmacies.<\/jats:p>","DOI":"10.3390\/ijms21103626","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T11:31:18Z","timestamp":1590060678000},"page":"3626","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-2324","authenticated-orcid":false,"given":"Andr\u00e9","family":"Fischer","sequence":"first","affiliation":[{"name":"Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-0175","authenticated-orcid":false,"given":"Manuel","family":"Sellner","sequence":"additional","affiliation":[{"name":"Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-652X","authenticated-orcid":false,"given":"Santhosh","family":"Neranjan","sequence":"additional","affiliation":[{"name":"Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-2680","authenticated-orcid":false,"given":"Martin","family":"Smie\u0161ko","sequence":"additional","affiliation":[{"name":"Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-5188","authenticated-orcid":false,"given":"Markus A.","family":"Lill","sequence":"additional","affiliation":[{"name":"Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_3","unstructured":"World Health Organisation (2020). Novel Coronavirus (2019-nCoV) Situation Reports, World Health Organisation."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22677","DOI":"10.1038\/srep22677","article-title":"Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, Z.M., Fu, J.F., Shu, Q., Chen, Y.H., Hua, C.Z., Li, F.B., Lin, R., Tang, L.F., Wang, T.L., and Wang, W. (2020). Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. WJP.","DOI":"10.1007\/s12519-020-00345-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_7","unstructured":"World Health Organisation (2020). International Health Regulations Emergency Committee on Novel Coronavirus in China, World Health Organisation."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Stoermer, M.J. (2020). Homology Models of the Papain-Like Protease PLpro from Coronavirus 2019-nCoV. ChemRxiv.","DOI":"10.26434\/chemrxiv.11799705"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.healthpol.2008.03.003","article-title":"The economic impact of SARS: How does the reality match the predictions?","volume":"88","author":"Smith","year":"2008","journal-title":"Health Policy"},{"key":"ref_10","first-page":"1","article-title":"Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation","volume":"1201","author":"Xu","year":"2020","journal-title":"BioRxiv"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S0140-6736(20)30305-6","article-title":"Reducing mortality from 2019-nCoV: Host-directed therapies should be an option","volume":"395","author":"Zumla","year":"2020","journal-title":"Lancet"},{"key":"ref_12","first-page":"1","article-title":"Deep learning based drug screening for novel coronavirus 2019-nCov","volume":"19","author":"Zhang","year":"2020","journal-title":"Preprints"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, Crystal Structure, Structure-Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liu, X., and Wang, X.J. (2020). Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J. Genet. Genom.","DOI":"10.1101\/2020.01.29.924100"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, X., Zhang, B., Jin, Z., Yang, H., and Rao, Z. (2020). The Crystal Structure of COVID-19 Main Protease in Complex with an Inhibitor N3, Protein DataBank.","DOI":"10.2210\/pdb6lu7\/pdb"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., and Zou, Q. (2020). Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. bioRxiv, 922922.","DOI":"10.1101\/2020.01.28.922922"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/JVI.01772-15","article-title":"Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors","volume":"90","author":"Raugi","year":"2016","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chen, Y.W., Yiu, C.P., and Wong, K.Y. (2020). Prediction of the 2019-nCoV 3C-like protease (3CLpro) structure_ virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.pdf.crdownload. ChemRxiv.","DOI":"10.26434\/chemrxiv.11831103.v1"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., and Li, X. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B.","DOI":"10.1016\/j.apsb.2020.02.008"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/bioinformatics\/btu626","article-title":"PDB-wide collection of binding data: Current status of the PDBbind database","volume":"31","author":"Liu","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.toxlet.2014.09.004","article-title":"OpenVirtualToxLab-A platform for generating and exchanging in silico toxicity data","volume":"232","author":"Vedani","year":"2015","journal-title":"Toxicol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coviro.2015.03.013","article-title":"Computational tools for epitope vaccine design and evaluation","volume":"11","author":"He","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/minf.201600024","article-title":"A Novel Multi-step Virtual Screening for the Identification of Human and Mouse mPGES-1 Inhibitors","volume":"91045543","author":"Corso","year":"2016","journal-title":"Mol. Inform."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1002\/jcc.21859","article-title":"Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime\/MM-GBSA calculation","volume":"32","author":"Du","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chemolab.2018.12.015","article-title":"Multistep virtual screening for rapid identification of G Protein-Coupled Receptors Kinase 2 inhibitors for heart failure treatment","volume":"185","author":"Ye","year":"2019","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.21873\/anticanres.14232","article-title":"3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase\/ Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells","volume":"40","author":"Kotowski","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gao, K., Nguyen, D.D., Wang, R., and Wei, G.W. (2020). Machine intelligence design of 2019-nCoV drugs. bioRxiv, 927889.","DOI":"10.1101\/2020.01.30.927889"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","article-title":"Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances","volume":"14","author":"Lionta","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cmdc.201800701","article-title":"A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E 2 Synthase-1 (mPGES-1) Inhibitors","volume":"14","author":"Shekfeh","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cmdc.201300134","article-title":"Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: Mechanistic and inhibitor design implications","volume":"8","author":"Lee","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1021\/acs.analchem.8b00504","article-title":"Reliable Strategy for Analysis of Complex Biosensor Data","volume":"90","author":"Multia","year":"2018","journal-title":"Anal. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17460441.2012.648612","article-title":"Going further than Lipinski\u2019s rule in drug design","volume":"7","author":"Walters","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10529-011-0845-8","article-title":"Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris","volume":"34","author":"Nguyen","year":"2012","journal-title":"Biotechnol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sl\u00e1mov\u00e1, K., Kape\u0161ov\u00e1, J., and Valentov\u00e1, K. (2018). \u201cSweet Flavonoids\u201d: Glycosidase-Catalyzed Modifications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072126"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(98)01101-6","article-title":"Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver \u03b2-glucosidase activity","volume":"436","author":"Day","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jff.2016.09.005","article-title":"Deglycosylation and absorption of marein, flavanomarein and taxifolin-7-O-\u03b2-D-glucopyranoside from capitula of Coreopsis tinctoria in rats and humans","volume":"27","author":"Han","year":"2016","journal-title":"J. Funct. Foods"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phymed.2008.10.002","article-title":"Determination and pharmacokinetic study of taxifolin in rabbit plasma by high-performance liquid chromatography","volume":"16","author":"Pozharitskaya","year":"2009","journal-title":"Phytomedicine"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Abd El-Hack, M.E., Alagawany, M., Elrys, A.S., Desoky, E.S.M., Tolba, H.M., Elnahal, A.S., Elnesr, S.S., and Swelum, A.A. (2018). Effect of forage moringa oleifera l. (moringa) on animal health and nutrition and its beneficial applications in soil, plants and water purification. Agriculture, 8.","DOI":"10.3390\/agriculture8090145"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Novo Belchor, M., Hessel Gaeta, H., Fabri Bittencourt Rodrigues, C., Ramos da Cruz Costa, C., de Oliveira Toyama, D., Domingues Passero, L.F., Dalastra Laurenti, M., and Hikari Toyama, M. (2017). Evaluation of Rhamnetin as an Inhibitor of the Pharmacological Effect of Secretory Phospholipase A2. Molecules, 22.","DOI":"10.3390\/molecules22091441"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.bmcl.2011.05.043","article-title":"Rhamnetin production based on the rational design of the poplar O-methyltransferase enzyme and its biological activities","volume":"21","author":"Lee","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bdd.605","article-title":"Quercetin pharmacokinetics in humans","volume":"29","author":"Moon","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1076029619847524","DOI":"10.1177\/1076029619847524","article-title":"Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin. Appl. Thromb."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14656566.2018.1454428","article-title":"Protease inhibitor therapy for hepatitis C virus-infection","volume":"19","author":"Stephan","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_47","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tang, N., Bai, H., Chen, X., Gong, J., Li, D., and Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. JTH, 1094\u20131099.","DOI":"10.1111\/jth.14817"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Xu, Z., Yao, H., Shen, J., Wu, N., Xu, Y., Lu, X., Zhu, W., and Li, L.J. (2020). Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells. ChemRxiv.","DOI":"10.26434\/chemrxiv.12039888"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","article-title":"Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment","volume":"27","author":"Deshmukh","year":"2019","journal-title":"Osteoarthr. Cartil."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13321-019-0330-2","article-title":"The nature of ligand efficiency","volume":"11","author":"Kenny","year":"2019","journal-title":"J. Cheminform."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drudis.2007.12.002","article-title":"Towards improving compound selection in structure-based virtual screening","volume":"13","author":"Waszkowycz","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1745-7254.2005.00010.x","article-title":"Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique","volume":"26","author":"Chen","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_55","unstructured":"Schrodinger LCC (2019). Maestro Small-Molecular Drug Discovery Suite 2019-4, Schrodinger."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/bioinformatics\/bts091","article-title":"Unipro UGENE: A unified bioinformatics toolkit","volume":"28","author":"Okonechnikov","year":"2012","journal-title":"Bioinformatics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bowers, K., Chow, E., Xu, H., Dror, R., Eastwood, M., Gregersen, B., Klepeis, J., Kolossvary, I., Moraes, M., and Sacerdoti, F.D. (2006, January 11\u201317). Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM\/IEEE SC 2006 Conference (SC\u201906), Tampa, FL, USA.","DOI":"10.1109\/SC.2006.54"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Shaw, D.E., Grossman, J.P., Bank, J.A., Batson, B., Butts, J.A., Chao, J.C., Deneroff, M.M., Dror, R.O., Even, A., and Fenton, C.H. (2014, January 16\u201321). Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer. Proceedings of the International Conference for High Performance Computing, Networking, Storage and Analysis, SC, New Orleans, LA, USA.","DOI":"10.1109\/SC.2014.9"},{"key":"ref_60","unstructured":"ChemAxon (2020, May 19). Marvin (v.20.4.0). Available online: http:\/\/www.chemaxon.com."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1021\/mp0700209","article-title":"The rule of five revisited: Applying log D in place of log P in drug-likeness filters","volume":"4","author":"Bhal","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15-Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: Improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bmcl.2009.02.010","article-title":"Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase\/helicase","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.bmcl.2009.07.009","article-title":"Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase\/helicase by dihydroxychromone derivatives","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1016\/j.bmcl.2011.03.034","article-title":"Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation","volume":"21","author":"Ryu","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","article-title":"Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_69","unstructured":"Diamond (2020). Main Protease Structure and XChem Fragment Screen, Diamond Light Source Ltd."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/ci300604z","article-title":"Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise","volume":"53","author":"Koes","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_74","first-page":"685","article-title":"Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus","volume":"17","author":"Tungol","year":"2011","journal-title":"J. Manag. Care Pharm. JMCP"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"ref_76","first-page":"1","article-title":"Open Babel","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.taap.2012.03.018","article-title":"VirtualToxLab\u2014A platform for estimating the toxic potential of drugs, chemicals and natural products","volume":"261","author":"Vedani","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.yrtph.2015.01.002","article-title":"Endocrine activity of alternatives to BPA found in thermal paper in Switzerland","volume":"71","author":"Goldinger","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2014The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3626\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:30:57Z","timestamp":1760175057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":79,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21103626"],"URL":"https:\/\/doi.org\/10.3390\/ijms21103626","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.11923239.v2","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]}}}